Blood-Brain Barrier Disruption Chemotherapy

John M. McGregor, Susan D. Bell, Nancy Doolittle, Tulio P. Murillo, Edward Neuwelt

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving the neurocognitive function and minimizing systemic toxicity. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as the primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors such as anaplastic oligodendroglioma and central nervous system metastases. Multicenter clinical trials using BBBD are in progress at centers participating in the blood-brain barrier (BBB) Consortium. Current and future clinical studies include delivery of mAbs across the BBB and novel imaging agents to monitor therapeutics.

Original languageEnglish (US)
Title of host publicationHandbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy
Subtitle of host publicationSecond Edition
PublisherElsevier Inc.
Pages145-153
Number of pages9
ISBN (Print)9780128121009
DOIs
StatePublished - Apr 24 2018

Fingerprint

Blood-Brain Barrier
Drug Therapy
Central Nervous System
Oligodendroglioma
Brain Neoplasms
Multicenter Studies
Lymphoma
Clinical Trials
Neoplasm Metastasis
Brain
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • Blood-brain barrier disruption
  • Brain tumors
  • Chemotherapy
  • Primary CNS lymphoma

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

McGregor, J. M., Bell, S. D., Doolittle, N., Murillo, T. P., & Neuwelt, E. (2018). Blood-Brain Barrier Disruption Chemotherapy. In Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition (pp. 145-153). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-812100-9.00010-3

Blood-Brain Barrier Disruption Chemotherapy. / McGregor, John M.; Bell, Susan D.; Doolittle, Nancy; Murillo, Tulio P.; Neuwelt, Edward.

Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition. Elsevier Inc., 2018. p. 145-153.

Research output: Chapter in Book/Report/Conference proceedingChapter

McGregor, JM, Bell, SD, Doolittle, N, Murillo, TP & Neuwelt, E 2018, Blood-Brain Barrier Disruption Chemotherapy. in Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition. Elsevier Inc., pp. 145-153. https://doi.org/10.1016/B978-0-12-812100-9.00010-3
McGregor JM, Bell SD, Doolittle N, Murillo TP, Neuwelt E. Blood-Brain Barrier Disruption Chemotherapy. In Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition. Elsevier Inc. 2018. p. 145-153 https://doi.org/10.1016/B978-0-12-812100-9.00010-3
McGregor, John M. ; Bell, Susan D. ; Doolittle, Nancy ; Murillo, Tulio P. ; Neuwelt, Edward. / Blood-Brain Barrier Disruption Chemotherapy. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition. Elsevier Inc., 2018. pp. 145-153
@inbook{cbc4c22a73f24d968d08377a9efdc7fb,
title = "Blood-Brain Barrier Disruption Chemotherapy",
abstract = "The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving the neurocognitive function and minimizing systemic toxicity. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as the primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors such as anaplastic oligodendroglioma and central nervous system metastases. Multicenter clinical trials using BBBD are in progress at centers participating in the blood-brain barrier (BBB) Consortium. Current and future clinical studies include delivery of mAbs across the BBB and novel imaging agents to monitor therapeutics.",
keywords = "Blood-brain barrier disruption, Brain tumors, Chemotherapy, Primary CNS lymphoma",
author = "McGregor, {John M.} and Bell, {Susan D.} and Nancy Doolittle and Murillo, {Tulio P.} and Edward Neuwelt",
year = "2018",
month = "4",
day = "24",
doi = "10.1016/B978-0-12-812100-9.00010-3",
language = "English (US)",
isbn = "9780128121009",
pages = "145--153",
booktitle = "Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Blood-Brain Barrier Disruption Chemotherapy

AU - McGregor, John M.

AU - Bell, Susan D.

AU - Doolittle, Nancy

AU - Murillo, Tulio P.

AU - Neuwelt, Edward

PY - 2018/4/24

Y1 - 2018/4/24

N2 - The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving the neurocognitive function and minimizing systemic toxicity. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as the primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors such as anaplastic oligodendroglioma and central nervous system metastases. Multicenter clinical trials using BBBD are in progress at centers participating in the blood-brain barrier (BBB) Consortium. Current and future clinical studies include delivery of mAbs across the BBB and novel imaging agents to monitor therapeutics.

AB - The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving the neurocognitive function and minimizing systemic toxicity. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as the primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors such as anaplastic oligodendroglioma and central nervous system metastases. Multicenter clinical trials using BBBD are in progress at centers participating in the blood-brain barrier (BBB) Consortium. Current and future clinical studies include delivery of mAbs across the BBB and novel imaging agents to monitor therapeutics.

KW - Blood-brain barrier disruption

KW - Brain tumors

KW - Chemotherapy

KW - Primary CNS lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85054625906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054625906&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-812100-9.00010-3

DO - 10.1016/B978-0-12-812100-9.00010-3

M3 - Chapter

AN - SCOPUS:85054625906

SN - 9780128121009

SP - 145

EP - 153

BT - Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy

PB - Elsevier Inc.

ER -